Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis.

AIMS Patients with AA and AL amyloidosis have a limited life-expectancy. The aim of this study was to investigate whether heart rate variability can predict mortality in these patients. METHODS AND RESULTS Twenty-two recently diagnosed patients with AA and 23 patients with AL amyloidosis were included. Fifteen patients (5 AA, 10 AL) died within 1 year. Twenty-four hour Holter recording was performed to quantify the mean of all normal to normal RR-intervals (mean NN) and the standard deviation of all normal to normal RR-intervals (SDNN). The SDNN predicted 1-year mortality in the total group of patients with amyloidosis. The median SDNN was 73 ms. In patients with an SDNN < or =73 ms, the risk of dying within 1 year was found to have increased 3.5-fold (P=0.0036; 95% CI 1.1-11.0). An SDNN < or =50 ms, a predictor of mortality in other patient groups, increased the risk of dying within 1 year 22-fold (P=0.0001; 95% CI 5.4-90.4). In contrast to patients with AA amyloidosis, in the subgroup analysis of patients with AL amyloidosis the SDNN remained a predictive parameter (SDNN < or =50 ms: risk ratio 11.5, 95% CI 2.4-56.2, P=0.0025). CONCLUSION The SDNN is a strong predictor of short-term mortality in patients with AL amyloidosis.

[1]  G. Husby.  Immunoglobulin-related (AL) amyloidosis. , 1983, Clinical and experimental rheumatology.

[2]  J. Seward,et al.  Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. , 1985, Journal of the American College of Cardiology.

[3]  J. Miller,et al.  Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. , 1987, The American journal of cardiology.

[4]  R. Kyle,et al.  Secondary Systemic Amyloidosis: Response and Survival in 64 Patients , 1991, Medicine.

[5]  J. Hamer,et al.  Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis. , 1992, European heart journal.

[6]  D. Stough,et al.  Extended survival of patients with primary systemic amyloidosis. , 1992, Cutis.

[7]  H. Thysell,et al.  Results, principles and pitfalls in the management of renal AA-amyloidosis; a 10-21 year followup of 16 patients with rheumatic disease treated with alkylating cytostatics. , 1993, The Journal of rheumatology.

[8]  Ferdinand J. Venditti,et al.  Reduced Heart Rate Variability and Mortalit Risk in an Elderly Cohort: The Framingham Heart Study , 1994, Circulation.

[9]  R. Simms,et al.  The epidemiology of AL and AA amyloidosis. , 1994, Bailliere's clinical rheumatology.

[10]  M. Skinner,et al.  Autonomic neuropathy in AL (primary) amyloidosis and its effect on survival , 1994 .

[11]  A. Malliani,et al.  Heart rate variability. Standards of measurement, physiological interpretation, and clinical use , 1996 .

[12]  G. Breithardt,et al.  Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. , 1996 .

[13]  T. Therneau,et al.  A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. , 1997, The New England journal of medicine.

[14]  F. Lombardi,et al.  Heart rate variability and cardiac failure , 1998, Heart.

[15]  J. Bigger,et al.  Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction , 1998, The Lancet.

[16]  R. Falk,et al.  The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. , 1998, QJM : monthly journal of the Association of Physicians.

[17]  A. Reyners,et al.  The assessment of autonomic function in patients with systemic amyloidosis: methodological considerations. , 1998, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[18]  T. Therneau,et al.  Long-term survival (10 years or more) in 30 patients with primary amyloidosis. , 1999, Blood.

[19]  A. Folsom,et al.  Low Heart Rate Variability in a 2-Minute Rhythm Strip Predicts Risk of Coronary Heart Disease and Mortality From Several Causes: The ARIC Study , 2000, Circulation.

[20]  Diagnosis and treatment of AL amyloidosis. , 2000, Clinical nephrology.

[21]  A. Camm,et al.  Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: a substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial). , 2000, Journal of the American College of Cardiology.

[22]  K. Simpson,et al.  Presentation, survival and prognostic markers in AA amyloidosis. , 2000, QJM : monthly journal of the Association of Physicians.

[23]  Bruce W. Dearstyne,et al.  Methodological Considerations , 2005 .